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To evaluate the 9-year incidence of cervical intraepithelial neoplasia grade 2 or worse (CIN2
+) and cumulative adherence to perform a next test in a cohort of women aged 40+ years
with no cervical screening cytology within a window of 5 years (underscreened women),
after baseline cervical cytology and HPV tests.
Methods
In Catalonia, Spain, co-testing with cytology and HPV test has been recommended in the
Public Health system since 2006 for underscreened women. In 2007, 1,594 women with
underscreened criteria were identified and followed through medical records form Pathologi-
cal Department. 9-year cumulative incidence of histologically confirmed CIN2+ and cumula-
tive adherence to perform a next test were estimated using Kaplan-Meier statistics.
Results
Follow-up was available for 1,009 women (63.3%) resulting in 23 women with. CIN2+
(2.3%). Of them, 4 women (17%) had both tests negative at baseline (3CIN2 and 1CIN3)
with cumulative incidence of CIN2+ of 0.4% (95% CI: 0.1–1.4) at 5-years and 1.3% (95% CI:
0.4–3.7) at 9-years. During the first year, the prevalence among women with both tests posi-
tive was 27.0% (95% CI: 13.0–50.6) for CIN2+. Lost to follow-up was higher among women
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with both tests negative compared to those with both positive tests (38.7% vs 4.2%, p-value
<0.001). 40.5% of the women HPV-/cyto- had a re-screening test during the 4 years follow-
ing the baseline, increasing until 53.5% during the 6 years of follow-up.
Conclusions
HPV detection shows a high longitudinal predictive value at 9-year to identify women at risk
to develop CIN2+. The data validate a safe extension of the 3-year screening intervals (cur-
rent screening interval) to 5-year intervals in underscreened women that had negative HPV
result at baseline. It is necessary to establish mechanisms to ensure screening participation
and adequate follow-up for these women.
Introduction
The implementation of screening programs for cervical cancer prevention, using cervical
cytology with a high coverage, has led to a reduction in the incidence and mortality of cervical
cancer up to 80%, due to the detection and treatment of precancerous lesions and incipient
cancers [1–3]. Unfortunately, this success has been mainly limited to high resource settings.
The recognition of the viral aetiology of cervical cancer has allowed the design of new
approaches for the screening of the disease with the aim of improving cytological screening
programs [4–6]. Data from randomized clinical trials (RCTs) have demonstrated the superior-
ity of HPV test for the detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+)
or cervical intraepithelial neoplasia grade 3 or worse (CIN3+) [7–11]. The combination of
both tests, cervical cytology and HPV tests, results in minor and statistically insignificant
improvements in sensitivity for CIN2+ and CIN3+ compared to HPV testing alone [12]. Four
of these clinical trials conducted in European countries and for which there are follow-up data
for at least two screening rounds (POBASCAM, SWEDESCREEN, ARTISTIC, and NTCC)
also revealed a substantial reduction of invasive cervical cancer in the HPV arm. This protec-
tive effect was observed starting 2.5 years after baseline in the total group of women screened
in both arms and increased over time [13].
However, the absence of screening, ranging from in 23 to 71%, is associated with an
increased mortality [14–18]. Our previous data indicated that 3 out of 4 cervical cancer cases
in Catalonia (Spain) arise from unscreened women, in agreement with other reports from the
country [19,20].
Aiming to reduce these preventable cases, the Autonomic Catalan government approved in
June 2006 a cervical cancer screening guidelines, aiming to identify women with suboptimal
screening history. This screening program was opportunistic. The guidelines recommended
co-testing with HPV DNA and cervical cytology in women aged 40 years or older having no
previous screening registered test in a window of 5 years, so called underscreened women [21].
In 2007, as part of the Catalan Institute of Oncology surveillance activities, a follow-up study
was initiated in a cohort underscreened women.
The objective of this study was to estimate the predictive value of the co-test of histologically
confirmed CIN2+ lesions. A previous analysis evaluating 3-year follow-up showed that this
strategy identified women at risk of CIN2+ that would have been missed by using cytology
alone [22]. We have extended now the follow-up to up nine years. Also, we evaluated cumula-
tive adherence to perform a next test in this group of women.
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This study is part of periodical evaluation reports on cervical cancer screening activities in the
public health system in Catalonia (Spain) carried out by the Catalan Institute of Oncology
[22,23].
This retrospective cohort includes 1,831 women with underscreened criteria identified in
2007. These women were offered a co-testing with cytology and HPV test at baseline and had
been follow-up for subsequent screening visits up to 2016. If the baseline result was negative
for both tests, a subsequent cytology test, as guidelines at the time recommended, was indi-
cated every 3 years until the age of 65 [21]. When cytology was positive, women were directly
referred to colposcopy. In HPV+/cyto- women, cytology was recommended at 6 moths. If this
cytology was negative, performing HPV test was recommended at 12 months, but if cytology
was positive women were referred to colposcopy evaluation.
The overall project was approved by the ethical committee of the Bellvitge University Hos-
pital (PR271/11). Any information regarding the identification of patients was anonymized
before analysis.
Follow-up
Follow-up was available through the computerized clinical history of the pathology laborato-
ries of the reference hospitals. During the follow-up period (2007–2016), date and results of
subsequent cytologies, biopsies and HPV test registered in clinical records were collected for
all participants. The participant laboratories included were: Hospital Universitari Dr. Josep
Trueta, Consorci hospitalari de Vic, Hospital Universitari Joan XXIII, Hospital del Mar, Hos-
pital Universitari de Bellvitge, Hospital General de Granollers, Hospital d’Althaia and Hospital
Germans Trias i Pujol.
If further concomitant tests were available, the highest cytological or histological grade of
abnormality was taking into account. Women with no more tests apart of those obtained at
the baseline were considered “lost to follow-up”.
Clinical records on pathology diagnosis and gynecological visits registered from 1st January
2007 to 31st of December 2016 were retrieved regularly every 18 months approximately.
Screening tests and gold standard test
Cervical cytology was largely based on conventional Pap smears and HC2 transport media was
used for HPV evaluation. If liquid based cytology was available, HPV and cytology tests were
performed using the same sample. All cytological results were classified according to the 2001
Bethesda system by the institution’s pathology teams [24]. Abnormal or positive cytology was
defined as atypical squamous cell of undetermined significance (ASC-US) or more severe
cytological diagnosis.
The HPV test was performed with the Hybrid Capture 2 test technology (HC2; Qiagen, Gai-
thersburg, MD, USA) which detects 13 high-risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59 and 68. A positive result was considered if attained or exceeded the FDA-approved
threshold of 1.0 relative light unit (RLU/CO). All HPV reference laboratories were part of a
quality control with kappa values over 90% [25].
All abnormal cytology results at the level of HSIL+ had to be histologically confirmed and
were classified according to the CIN classification [26].
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Statistical analysis
All women identified during 2007 with underscreened criteria, who had been screened by co-
test were included. Included laboratories were health area referent for cytology, HPV and his-
tology data and were able to provide follow-up information on the study population.
We estimated:
1. Cumulative and annual incidence of CIN2+ and CIN3+. The main event of interest was
the development of CIN2+ or CIN3+ along the follow-up period. CIN2+ result included all
histologically confirmed diagnoses of CIN2, CIN3, adenocarcinoma and invasive cervical
carcinoma. In CIN3+ result, CIN2 is not included. A variable called “final diagnosis” was
created including three categories: 1) women who had developed a CIN2+ or CIN3
+ throughout the follow-up period, 2) women with a diagnosis other than CIN2+ or CIN3
+, and 3) women with only the baseline tests that were considered lost to follow-up because
of missing data. A woman was censored for follow-up if a CIN2+ lesion was identified, or
when there was a surgical treatment for a CIN1 lesion, or in case of hysterectomy for non-
cervical causes. In these cases, the woman contributed time until the diagnosis of CIN2+ or
until time of surgical treatment or hysterectomy. Remaining women or in case of death for
causes other than cervical cancer, the contributing time was accounted for until the last
recorded test. For women with a baseline positive test, at least two negative tests (either
HPV or cytology) were necessary to be registered as having a negative final diagnosis. For
women with a negative result of the two tests at baseline, they were coded as negative at the
end of follow-up if they had subsequent negative test results.
2. Cumulative adherence to perform a next test. Among women with HPV-/cyto- at base-
line, any test performed after 180 days following baseline tests including HPV test, cytology
or cervical biopsy were all taken into account. This was done to avoid including additional
tests not related to screening that could have been performed before (e.g.: follow-up of
infections, such as Candia Albicans, Trichomona Vaginalis, etc.). Among women HPV
+/cyto-, tests performed at least 45 days after baseline were considered to not interfere with
other tests performed concomitantly with the baseline ones. Among women HPV-/cyto
+ and HPV+/cyto+, all subsequent tests performed, after baseline ones were considered
without restriction.
A woman was censured at the time that she had the next cytology, HPV test or cervical
biopsy (event) registered after baseline according to the established criteria. The contribution
time of that woman was time between baseline tests and the performance of next test. Women
did no additional tests were censored on the date of baseline. In case of hysterectomy not due
to cervical cancer, or death not related to cervical cancer, women was censored at the date of
that event and considered of non-related event. If no date of death was available, the last date
of woman’s test was used. If none was available, it was considered the date of baseline.
Results for continuous variables were given as mean values, and for categorical variables as
percentages. We used chi-square test to compare proportions between groups. The percentage
of cumulative incidence of histologically confirmed CIN2+ and CIN3+ lesions and its 95%
confidence intervals (CI) as well as the cumulative adherence to perform a next test were esti-
mated and graphically represented using the Kaplan-Meier curves at 1, 3, 5 and 9 years. Data
are presented according to the combination of baseline results of cytology and HPV tests up to
9 years follow-up. Incidence rates were calculated in person-years per 100 women. Pairwise
comparisons between cumulative incidence curves were evaluated using log-rank test. Also,
annual incidence rates of CIN2+ and CIN3+ lesions were calculated at 3, 5 and 9 years, as the
number of cases per 100 women/year, according to all combinations of baseline test results,
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with their 95% CI (S1 Table). In all cases, time was expressed in years. All statistical tests were
two tailed, and p-values below 0.05 were considered statistically significant.
To estimate number of women at risk during the study period and accounting for variabil-
ity, person-years were estimated as number of years from baseline date of initial screening
tests (HPV/cytology) to date of censorship or until end of follow-up period.
Data analyses were carried out with R software version 3.3.2 (R Core Team (2015). R: A lan-
guage and environment for statistical computing. R Foundation for Statistical Computing,
Vienna, Austria. URL https://www.R-project.org/).
Results
At baseline1,831 women were included in the study, with a mean age of 54.4 years old at base-
line (range 40–88). Double negative tests results were detected in 92.4% of women (n = 1,692)
while 1.3% (n = 24) had both tests positive. 6.7% (n = 123) of women were HPV positive irre-
spective of cytology result, and 2.2% (n = 40) had a positive cytology regardless of HPV result
(Fig 1).
At baseline, 231 women out of 1,831 were over 65 years of age with negative result in both
tests (HPV/cytology) and were informed, consequently, to stop further cervical cancer screen-
ing. Six women died for reasons other than cervical cancer before the performance of a new
test, so they were excluded, leaving a total of 1,594 women for being followed-up. Of these,
Fig 1. Flowchart of the study population. Underscreened women are defined as women older than 39 years with no records on cervical cytology during the
previous 5 years.
https://doi.org/10.1371/journal.pone.0237988.g001
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1,009 (63.3%) women had a complete follow-up during the study period (Fig 1). In 36.7% of
women, there was no evidence of a new test during the 9-year follow-up period. Most of these
women classified as "lost to follow-up" were women with both baseline negative tests instead
of women with both positive results (38.7% vs. 4.2%, p-value <0.001).
During the 9 years of follow-up, a total of 23 women with histologically confirmed CIN2
+ lesions were diagnosed, including 9 CIN3, 3 squamous carcinomas and one adenocarci-
noma. The mean age of women at CIN2+ diagnosis was 49.3 years (range 40–67 years old).
Eleven women (47.8%) out of the 23 CIN2+ cases were diagnosed among women with nega-
tive cytology but HPV positive test (Fig 1). Four cases of CIN2+ were diagnosed among
women with both negative tests: 3 CIN2 and 1 CIN3. The four cervical cancers (an adenocarci-
noma stage IA and 3 squamous carcinoma all of them stage IIB) were diagnosed among
women with both positive cytology and HPV results. The average time between first abnormal
test and final cancer diagnosis was 2.7 years (range: 0.0–8.4 years).
Among CIN2+ cases, 70% (n = 16) were diagnosed within the first 3 years of follow-up, and
all of them were positive for HPV, but only 7 had an abnormal cytology. Of the remaining 30%
of cases (n = 7) diagnosed after 3 years of follow-up, one case had an abnormal cytology
(14.3%) and the HPV test identified 3 cases (43%). Among women with both tests being nega-
tive, 4 had a CIN2+ with an average time until diagnosis of 5.7 years (range of 4.4–7.5 years).
Table 1 shows the cumulative incidences estimates of histologically confirmed CIN2+ and
CIN3+ by baseline screening tests results and time period of follow-up. Remarkably, the
cumulative incidence of CIN2+ among women with both negative tests was 0.4% (95% CI:
0.1–1.4) at 5 years and 1.3% (95% CI: 0.4–3.7) at 9 years, while, the incidence of CIN3+ was
zero in the first 5 years of follow-up and 0.3% (95% CI: 0.0–2.2) at 9 years. Among women
with both positive tests at baseline, the cumulative incidence were 27.0% (95% CI: 13.0–50.6)
during the first year for CIN2+ and 21.7% (95% CI: 9.7–44.6) for CIN3+, increasing up to
32.6% (95% CI: 16.9–56.9) and 27.8% (95% CI: 13.3–52.2) for CIN2+ and CIN3+ respectively
at 3 and 5 years.
Annual incidence rates of CIN2+ and CIN3+ lesions at 3, 5 and 9 years were detailed in the
supporting information (S1 Table).
Fig 2 summarizes graphically the cumulative risk of developing CIN2+ and CIN3+ lesions
over time for the different combinations of test results at baseline. Among all women with a
positive cytology, only those with an HPV positive test developed CIN2+ or CIN3+. The
cumulative risk of developing CIN3+ lesions among those women with a negative HPV test
remained very low throughout the 9 years of follow-up. The risk of developing CIN3+ among
negative HPV women regardless of cytology result at 5 years was zero (Table 1).
Differences between the combination of screening test results and having a CIN2+ or CIN3
+ lesion were statistically significant according to the log-rank test (p-value <0.001) an
explained by the impact of HPV test and not by cytology results. When HPV negative women
with negative and positive cytology were compared, these differences were not statistically sig-
nificant (p-value = 0.8 for CIN2+ and p-value = 0.9 for CIN3+). Thus, HPV test was crucial in
the CIN2+ risk stratification.
Table 2 and Fig 3 show the cumulative adherence to perform a next cytology, HPV test or
cervical biopsy, along time by results of baseline screening tests. We observed that among
women with both negative tests at baseline, in which the recommended interval for re-screen-
ing was after 3 years, only 40.5% had a next test registered during the 4 years from the baseline
and 53.5% returned to perform a test along the following 6-years after baseline. Only 60.2% of
these women had a next test recorded during the 9-years follow-up period, evidencing a poor
adherence of these women to screening protocol recommendations. According to screening
protocol recommendations, in HPV+/cyto- women, a cytology and colposcopy should be
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performed between 6 and 12 months or an HPV test at 12 months as follow-up. We observed
that the 67.3% of these women had a follow-up test during the following 2 years from baseline,
increasing to 74.5% before 3 years. However, in 16.3% of women there was no additional test
recorded during the 9-year follow-up. Most women with a positive cytology at baseline and
regardless of the HPV result had a follow-up test in the following year.
Discussion
HPV testing in cervical cancer screening among underscreened women over age 39 has shown
an excellent longitudinal predictive value for the detection of CIN2+ and CIN3+ lesions at 9
years of follow-up, in both HPV positive and HPV negative women. The inclusion of HPV test
in addition to cervical cytology in women at risk of cervical cancer identified all CIN3+ cases
but one, at year 9 since baseline, while cytology missed 6 cases of CIN3+. These results are con-
sistent with our evaluation at 3 years and with the literature, supporting HPV as a standalone
primary screening test [22], and that HPV testing is more accurate than cytology to predict dis-
ease also among underscreened women.
Women with HPV negative results, regardless of cytology result had a low risk for CIN2
+ and CIN3+, remaining low over time. In our study, no cases with CIN3+ were observed

























HPV positive—cyto positive (N = 24)
Period of time (years)
1 14 6 4 27.0 13.0 50.6 5 5 21.7 9.7 44.6
3 7 1 6 32.6 16.9 56.9 1 6 27.8 13.3 52.2
5 5 0 2 32.6 16.9 56.9 0 2 27.8 13.3 52.2
9 . . . . . . . . . . .
HPV positive—cyto negative (N = 99)
Period of time (years)
1 65 5 29 6.5 2.8 14.9 3 31 4.1 1.3 12.2
3 38 4 23 14.0 7.4 25.6 1 26 5.8 2.2 14.9
5 20 1 17 17.1 9.2 30.4 0 18 5.8 2.2 14.9
9 1 1 18 24.6 12.0 46.5 1 18 14.4 4.3 42.2
HPV negative—cyto positive (N = 16)
Period of time (years)
1 9 0 7 0.0 0.0 0.0 0 7 0.0 0.0 0.0
3 8 0 1 0.0 0.0 0.0 0 1 0.0 0.0 0.0
5 6 0 2 0.0 0.0 0.0 0 2 0.0 0.0 0.0
9 1 0 5 0.0 0.0 0.0 0 5 0.0 0.0 0.0
HPV negative—cyto negative (N = 1,455)
Period of time (years)
1 856 0 599 0.0 0.0 0.0 0 599 0.0 0.0 0.0
3 725 0 131 0.0 0.0 0.0 0 131 0.0 0.0 0.0
5 498 2 225 0.4 0.1 1.4 0 227 0.0 0.0 0.0
9 26 2 470 1.3 0.4 3.7 1 471 0.3 0.0 2.2
CIN2+ included cervical intraepithelial neoplasia grade 2 and 3 and cervical carcinoma. CIN3+ included cervical intraepithelial neoplasia grade 3 and cervical
carcinoma. CIN2+ and CIN3+ incidence rates were calculated in person-years per 100 women.
https://doi.org/10.1371/journal.pone.0237988.t001
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among HPV negative women at 5 years and the risk increased still a very low level to 0.3%
(95% CI, 0.1–2.3%) at 9 years. Additionally, among all women with a positive cytology, only
those with a concomitant HPV positive test developed cervical pathology. In the RCT Athena
Study, a study conducted in US among women aged 25 years or older attending routine
Fig 2. Cumulative incidence of developing a histologically confirmed CIN2+ (A) or CIN3+ (B) by baseline co-testing
results among underscreened women. Underscreened women are defined as women older than 39 years with no
records on cervical cytology during the previous 5 years. CIN2+ included cervical intraepithelial neoplasia grade 2 and
3 and cervical carcinoma. CIN3+ included cervical intraepithelial neoplasia grade 3 and cervical carcinoma.
https://doi.org/10.1371/journal.pone.0237988.g002
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HPV positive - cyto positive (N = 24)
Period of time (years)
1 2 22 0 91.7 76.7 98.6
2 1 1 0 95.8 82.4 99.7
3 1 0 0 95.8 82.4 99.7
4 1 0 0 95.8 82.4 99.7
5 1 0 0 95.8 82.4 99.7
6 1 0 0 95.8 82.4 99.7
7 1 0 0 95.8 82.4 99.7
8 1 0 0 95.8 82.4 99.7
9 1 0 0 95.8 82.4 99.7
HPV positive—cyto negative (N = 99)
Period of time (years)
1 55 43 1 43.9 34.7 54.3
2 32 23 0 67.3 58.0 76.4
3 25 7 0 74.5 65.6 82.6
4 21 4 0 78.6 70.0 86.1
5 19 2 0 80.6 72.3 87.7
6 16 3 0 83.7 75.7 90.2
7 16 0 0 83.7 75.7 90.2
8 16 0 0 83.7 75.7 90.2
9 14 0 2 83.7 75.7 90.2
HPV negative—cyto positive (N = 16)
Period of time (years)
1 5 10 1 65.9 42.8 87.4
2 4 1 0 72.7 49.6 91.5
3 4 0 0 72.7 49.6 91.5
4 4 0 0 72.7 49.6 91.5
5 4 0 0 72.7 49.6 91.5
6 4 0 0 72.7 49.6 91.5
7 4 0 0 72.7 49.6 91.5
8 4 0 0 72.7 49.6 91.5
9 4 0 0 72.7 49.6 91.5
HPV negative—cyto negative (N = 1,455)
Period of time (years)
1 1,386 67 2 4.6 3.6 5.8
2 1,230 156 0 15.3 13.6 17.3
3 1,085 145 0 25.3 23.2 27.6
4 863 220 2 40.5 38.0 43.1
5 747 116 0 48.5 45.9 51.1
6 674 73 0 53.5 51.0 56.1
7 642 32 0 55.7 53.2 58.3
8 586 49 7 59.1 56.6 61.6
(Continued)
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cervical screening, the cumulative incidence of CIN3+ after 3 years for women with double
negative tests (cytology + HPV) was 0.3% (95% CI, 0.1–0.6%) comparable to that observed
among women having been tested with HPV only, and more than twice among women with
negative cytology [27]. In another RCT carried out in Sweden, the cumulative incidence of
CIN3+ was 0.89% among HPV negative women at 13 years of follow-up, similar to that
reported among women with a negative co-test (0.84%), in contrast with a cumulative inci-
dence of 1.54% in women with negative cytology [28]. In the POBASCAM RCT the cumulative
CIN3+ incidence was 0.56% among HPV negative women after 3 rounds of screening (14
years follow-up) [29]. Therefore, HPV test allows for a better risk stratification with no clear of
co-testing [13,27,28]. Among women with both tests being negative, 4 had a CIN2+ with an
average time until diagnosis of 5.7 years (range of 4.4–7.5 years).
On the other hand, in our study, the average time to final diagnosis of a CIN2+ lesion in
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9 459 14 113 60.2 57.6 62.7
Underscreened women are defined as women older than 39 years and with no records on cervical cytology during the previous 5 years. Follow-up intervals established
according to the protocol are: 1) 3-years among women negative for both tests, 2) between 6 months and 1-year among women positive for HPV but with negative
cytology, 3) immediate follow-up using colposcopy for the remaining cases.
https://doi.org/10.1371/journal.pone.0237988.t002
Fig 3. Cumulative adherence to perform a next test, stratified by baseline co-testing results among underscreened
women. Underscreened women are defined as women older than 39 years and with no records on cervical cytology
during the previous 5 years. Follow-up intervals established according to the protocol are: 1) 3-years among women
negative for both tests, 2) between 6 months and 1-year among women positive for HPV but with negative cytology, 3)
immediate follow-up using colposcopy for the remaining cases.
https://doi.org/10.1371/journal.pone.0237988.g003
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CIN3+ diagnosis (for the only one case). Our results support that HPV can be an excellent pri-
mary test that provides security to go beyond a 3-year screening interval, also in underscreened
women. In the European RCTs, risk of CIN3+ among women with a negative screening test at
baseline was found to be about the same after six years with HPV screening than after three
years with cytology screening [13], suggesting that screening intervals could safely be extended
for women who screen with HPV test. Furthermore, the risk of CIN2+ or CIN3+ among HPV
negative women was low and maintained the same protection even after 13 years of follow-up
[28]. This strong scientific evidence are now being reflected in national guidelines around the
world [30–32]. The European guidelines for cervical cancer prevention recommend a screen-
ing interval of at least 5 years which may extend up to 10 years for women with a negative
HPV primary test result. This range of intervals may vary by age and women’s screening his-
tory [31].
However, having a screening test with a higher sensitivity but a lower specificity leads to
overdetection and needs to be balanced by the benefits of an early detection. To avoid detec-
tion of HPV positive cases that are unlikely to develop cervical cancer, several authors have
proposed to restrict the number of HPV types included in the HPV assays, given that the risk
of developing a CIN3+ is very low for some genotypes such as 39, 51, 56, 59, 68 [33,34]. Recent
studies have seen that the risk of developing a 7-year CIN3+ for these types is less than 5% and
80% of these infections are no longer detected in three years [34]. On the other hand, RCTs of
HPV based screening have found that the higher detection of CIN2+ at baseline is followed by
a reduction of these lesions in subsequent screening rounds [28–30]. These studies showed
that the early increases detection of CIN2+ with HPV based screening does not represent a big
burden of overdiagnosis but it suggests an earlier detection of cervical disease [13,30]. In our
study, we included women above age 39, in whom regressive lesions are likely to be less com-
mon as compared to young women[35]. In our study, 86% of CIN2+ diagnosed among
women those with both positive tests were detected during the first year and in most cases,
screening tests were part of the diagnosis of CIN2+. In addition, having both positive tests gen-
erates a much higher risk during the first year than having one of them negative (27.0% vs.
6.5%). But above all, according to the data from our study, the risk increased if the positive test
was the HPV test. Subsequently, the risk of diagnosis of these lesions decreases in later years.
In fact, in our study, the cumulative risk of having CIN2+ lesions had a steep rise between the
first 12 months and the third year, followed by stabilization or slow increase between the third
and fifth year of follow-up. RCTs have also shown a reduction in detection of high grade
lesions in the second rounds compared with the first round, highlighting the impact of using
the HPV test in screening when it is compared with cytological screening [28,29]. This benefit
of the HPV test could be critical for underscreened women that have persistently poor adhe-
sion to recommendations. In our study, we found that one third of total women did not return
to screening after baseline tests. Among double negative women, only 40.5% had a re-screen-
ing before the next 4 years and 53.5% before the 6 years of follow-up, demonstrating that
despite having participated in the screening activities, they did not meet the established inter-
vals and most of those who returned, they did so at longer than recommended intervals.
Unfortunately, we do not know if these women have searched care elsewhere. Under opportu-
nistic screening approaches, loss to follow-up is common. We have shown that inviting these
women can quickly revert the situation [36]. The use of personal reminders increased signifi-
cantly screening participation even if only an invitation letter with a scheduled visit was used
[36,37]. Generally, in organized programs, higher adherence to the screening programs is
attained [37–39]. As well, women may perceive themselves to be at low risk of cervical cancer,
and thus delay their attendance at screening as occurred in a Norwegian study [40]. A study
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carried out in Sweden also pointed out that women have a comprehensive rationale for post-
poning cervical screening, yet they do not view themselves as non-attenders [41].
On the other hand, a certain proportion of women, 17.2% of HPV positive and negative
cytology and in 25% HPV negative women with a positive cytology, had no record of a second
screening visit. A poor information or full understanding of a positive test could affect follow-
up visit as has been seen elsewhere [42,43]. Good and comprehensive information remains a
special need, particularly when the HPV test is positive, but the cytology does not detect any
abnormality. The fact of having a negative cytology, associated with a lack of knowledge about
the superiority of HPV tests in predicting disease, can give a false sense of security as observed
also by others [40,41]. Some studies have shown that attendance at repeated tests is poor, par-
ticularly after a normal cytological test, reaching losses of 40% within the established one-year
follow-up intervals [44,45]. Adequate communication is necessary to improve adequate man-
agement of screen positive women. For women who find it difficult to attend appointments,
there may be substantial advantage to being able to self-collect at home.
Study limitations and strengths
This is an evaluation of the implementation of screening guidelines and data are thus limited
to that available at the health information system of public health sector. Any additional infor-
mation such as socioeconomic profile or individual characteristics that could affect participa-
tion in screening activities was not available. The yield of disease among the subgroup of
women with HPV-/cyto+, at baseline (only 16 women), should be considered with caution,
due to the low number of women under this stratum.
A strong point of our study lies in the monitoring over a period of 9 years the use of pathol-
ogy laboratory registries. Although there could be some sub-registration if women decided
after a given test, to go to a private services, this is however, suspected to be minimal among
those having had a baseline visit although no routine registration exist. The HPV test used
(HC2) is a robust test with high interlaboratory reproducibility among all reference laborato-
ries in Catalonia [25].
Conclusions
HPV test in cervical cancer screening, among underscreened women over age 39, shows a
high longitudinal predictive value at 9 years to identify women at risk to develop CIN2+, in
both HPV+ and HPV- women. The data validate a safe extension of the 3-year screening inter-
vals (current screening interval) to 5-year intervals in underscreened women with a negative
HPV result. Underscreened women had persistently poor adhesion to screening recommenda-
tions, so it is necessary to establish mechanisms to ensure re-screening participation within the
established intervals in women with negative tests and compliance with adequate follow-up in
women with positive tests.
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